• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bristol-Myers Squibb (NY: BMY )

    54.32 -1.45 (-2.60%)
    Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Bristol-Myers Squibb

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    65 66 Next >
    Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
    On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79. 
    Via Investor's Business Daily
    Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
    Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline. 
    Via Benzinga
    Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
    The major indexes declined, but haven't fallen apart. 
    Via Investor's Business Daily
    Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
    Via Benzinga
    Unveiling 11 Analyst Insights On Bristol-Myers Squibb
    Via Benzinga
    Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
    From Bristol Myers Squibb
    Via Business Wire
    Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
    Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
    Via Benzinga
    Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
    BMY earnings call for the period ending September 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
    Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates. 
    Via Benzinga
    Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
    The pharma giant has been trading tightly in recent weeks. 
    Via Investor's Business Daily
    Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
    From Bristol Myers Squibb
    Via Business Wire
    Markets Give Back Gains As Hovering Continues
    Market indexes could not hold onto earlier gains this afternoon, and all closed near session lows. The moves were mild, though — as we’ve stated in this space previously, the big news the market is... 
    Via Talk Markets
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
    Via Benzinga
    Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
    Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
    Via Benzinga
    Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
    From Bristol Myers Squibb
    Via Business Wire
    What Lies In Store For Healthcare ETFs In Q3 Earnings?
    The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
    Via Talk Markets
    Topics ETFs
    800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
    EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
    Via Benzinga
    Why Is Evotec Stock Gaining Today?
    Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment. 
    Via Benzinga
    Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
    There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
    Via Talk Markets
    Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
    The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
    Via Investor's Business Daily
    Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
    HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
    Via Benzinga
    Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
    Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024. 
    Via The Motley Fool
    Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
    The company could have a long path ahead to reimbursement and, ultimately, sales. 
    Via Investor's Business Daily
    Exposures Product Safety
    Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
    Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
    Via Talk Markets
    Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
    Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals. 
    Via Benzinga
    Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
    The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic. 
    Via Benzinga
    Exposures Product Safety
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
    Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
    Via Benzinga
    Topics Artificial Intelligence Stocks
    Exposures Artificial Intelligence US Equities
    Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
    Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion stake may spark a turnaround. 
    Via Benzinga
    Exposures COVID-19
    Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
    FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients. 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    65 66 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.